New award for melatonin tablets with marlex pharmaceuticals INC. Base year ordering period is september 15, 2026 - september 14, 2027, with four one-year options.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79726D0034
- Awardee
-
Marlex Pharmaceuticals Inc. UEI VSSNJEFMPLB3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Melatonin Tablets Pre-Solicitation · 36E79726R0015 · Posted Feb 25, 2026
- Last date to order 9% complete
- IDV ceiling
- $5,939,023.25
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 10 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract to Marlex Pharmaceuticals Inc. for melatonin tablets and capsules, with a contract ceiling of $5,939,023.25, effective September 15, 2026.
The contract carries no set-aside designation. Place of performance spans nationwide distribution through the VA's and Department of Defense pharmaceutical prime vendor programs, supporting the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center.
The originating solicitation (RFP 36E79726R0015) sought melatonin capsules and tablets in three formulations: 1-milligram, 3-milligram, and 5-milligram, with anticipated annual demand of 35,394 bottles, 1,363,153 bottles, and 439,142 bottles respectively. Products must meet specific packaging requirements including 120-cubic-centimeter minimum volume bottles with safety caps, VA-compliant labels, and cylindrical bottles with a minimum 5.75-inch circumference.
The base ordering period runs September 15, 2026, through September 14, 2027, with four one-year options extending the potential contract duration through September 14, 2030. The contract implements Executive Order 14398 regarding diversity, equity, and inclusion discrimination policy.
Marlex Pharmaceuticals Inc. is a minority-owned, Subcontinent Asian American-owned small disadvantaged business headquartered in New Castle, Delaware, that manufactures and supplies generic pharmaceutical tablets to federal healthcare systems.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79726D0034?
36E79726D0034 was awarded to Marlex Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on September 15, 2026.
How much is contract 36E79726D0034 worth?
36E79726D0034's own ceiling is $5,939,023.
Who can order from contract 36E79726D0034?
36E79726D0034 is a single award indefinite delivery contract.
Was contract 36E79726D0034 competed?
The extent of competition for 36E79726D0034 was full and open competition. The government received 10 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV